Inhibikase Therapeutics (IKT) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 150.0% versus a gain of 15.1%. Over five years, IKT leads with a -83.5% price change compared with -92.4% for IPSC. Inhibikase Therapeutics is the larger company by market cap ($266.5 million vs $264.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | IPSC |
|---|---|---|
| Share price | $1.91 | $1.46 |
| Market cap | $266.51M | $264.37M |
| 1-day change | -1.55% | +14.06% |
| YTD return | -6.83% | +46.73% |
| 1-year return | +15.06% | +150.00% |
| 5-year return | -83.51% | -92.44% |
| EPS (TTM) | $-0.43 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $3.04 |
| 52-week low | $1.33 | $0.435 |
| Distance from 52-week high | -26.82% | -51.97% |
| Analyst consensus | none | buy |
| Avg. price target upside | +214.14% | +225.34% |
| Average volume | 652.84K | 649.61K |
| Shares outstanding | 139.54M | 181.08M |
| Employees | 35 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed IKT by 134.9 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
IKT vs IPSC FAQ
Which is bigger, Inhibikase Therapeutics or Century Therapeutics?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $266.51M compared with $264.37M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IKT or IPSC?
IPSC returned +150.00% over the past 12 months, compared with +15.06% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.